<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25316839</PMID><DateCompleted><Year>2014</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>210 Suppl 1</Volume><Issue>Suppl 1</Issue><PubDate><Year>2014</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Assessing population immunity in a persistently high-risk area for wild poliovirus transmission in India: a serological study in Moradabad, Western Uttar Pradesh.</ArticleTitle><Pagination><StartPage>S225</StartPage><EndPage>S233</EndPage><MedlinePgn>S225-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/infdis/jiu204</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Moradabad district in Uttar Pradesh reported the highest number of paralytic polio cases in India during 2001-2007. We conducted a study in Moradabad in 2007 to assess seroprevalence against poliovirus types 1, 2, and 3 in children 6-12 and 36-59 months of age to guide future strategies to interrupt wild poliovirus transmission in high-risk areas.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Children attending 10 health facilities for minor illnesses who met criteria for study inclusion were eligible for enrollment. We recorded vaccination history, weight, and length and tested sera for neutralizing antibodies to poliovirus types 1, 2, and 3.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Poliovirus type 1, 2, and 3 seroprevalences were 88% (95% confidence interval [CI], 84%-91%), 70% (95% CI, 66%-75%), and 75% (95% CI, 71%-79%), respectively, among 467 in the younger age group (n=467), compared with 100% (95% CI, 99%-100%), 97% (95% CI, 95%-98%), and 93% (91%-95%), respectively, among 447 children in the older age group (P&lt;.001 for all serotypes).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This seroprevalence study provided extremely useful information that was used by the program in India to guide immunization policies, such as optimizing the use of different OPV formulations in vaccination campaigns and strengthening routine immunization services. Similar surveys in populations at risk should be performed at regular intervals in countries where the risk of persistence or spread of indigenous or imported wild poliovirus is high.</AbstractText><CopyrightInformation>&#xa9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Deshpande</LastName><ForeName>Jagadish M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Enterovirus Research Center, Haffkine Institute, Mumbai.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahl</LastName><ForeName>Sunil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>National Polio Surveillance Project, World Health Organization (WHO) Country Office for India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Bidyut K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>Public Health Foundation of India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Est&#xed;variz</LastName><ForeName>Concepci&#xf3;n F</ForeName><Initials>CF</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sharma</LastName><ForeName>Shamila</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>UNICEF India, New Delhi, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolff</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sethi</LastName><ForeName>Raman</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>National Polio Surveillance Project, World Health Organization (WHO) Country Office for India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathyarch</LastName><ForeName>Surendra K</ForeName><Initials>SK</Initials><AffiliationInfo><Affiliation>National Polio Surveillance Project, World Health Organization (WHO) Country Office for India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Vibhor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Polio Surveillance Project, World Health Organization (WHO) Country Office for India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gary</LastName><ForeName>Howard E</ForeName><Initials>HE</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pallansch</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Centers for Disease Control and Prevention, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafari</LastName><ForeName>Hamid</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>WHO, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>001</GrantID><Acronym>WHO_</Acronym><Agency>World Health Organization</Agency><Country>International</Country></Grant><Grant><GrantID>CC999999</GrantID><Acronym>ImCDC</Acronym><Agency>Intramural CDC HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011055">Poliovirus Vaccine, Oral</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007194" MajorTopicYN="N" Type="Geographic">India</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011051" MajorTopicYN="N">Poliomyelitis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011055" MajorTopicYN="N">Poliovirus Vaccine, Oral</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016036" MajorTopicYN="N">Seroepidemiologic Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Moradabad</Keyword><Keyword MajorTopicYN="N">OPV formulations</Keyword><Keyword MajorTopicYN="N">immunization policies</Keyword><Keyword MajorTopicYN="N">immunogenecity</Keyword><Keyword MajorTopicYN="N">neutralizing antibodies</Keyword><Keyword MajorTopicYN="N">seroprevalence</Keyword><Keyword MajorTopicYN="N">wild poliovirus</Keyword></KeywordList><CoiStatement><b><i>Potential con</i></b>fl<b><i>icts of interest</i>.</b> All authors: No reported conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>12</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>7</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25316839</ArticleId><ArticleId IdType="mid">NIHMS1913142</ArticleId><ArticleId IdType="pmc">PMC10325558</ArticleId><ArticleId IdType="doi">10.1093/infdis/jiu204</ArticleId><ArticleId IdType="pii">jiu204</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication&#x2013;India, January 2005&#x2013;June 2006. MMWR Morb Mortal Wkly Rep 2006; 55:772&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">16855526</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowdle WR, Birmingham ME. The biologic principles of poliovirus eradication. J Infect Dis 1997; 175(suppl 1):S286&#x2013;92.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110371</ArticleId><ArticleId IdType="pubmed">9203732</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication&#x2013;India, 1998. Morb Mortal Wkly Rep 1998; 47:778&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">9769136</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication&#x2013;India, January 2004&#x2013;May 2005. MMWR Morb Mortal Wkly Rep 2005; 54:655&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16001016</ArticleId></ArticleIdList></Reference><Reference><Citation>Bottiger M The elimination of polio in the Scandinavian countries. Public Health Rev 1993; 94:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">8041886</ArticleId></ArticleIdList></Reference><Reference><Citation>Diedrich S, Claus H, Schreier E. Immunity status against poliomyelitis in Germany: determination of cut-off values in International Units. BMC Infect Dis 2002; 2:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC101379</ArticleId><ArticleId IdType="pubmed">11943068</ArticleId></ArticleIdList></Reference><Reference><Citation>Fine PE, Carneiro IA. Transmissibility and persistence of oral polio vaccine viruses: implications for the global poliomyelitis eradication initiative. Am J Epidemiol 1999; 150:1001&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10568615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghendon Y, Robertson SE. Interrupting the transmission of wild polioviruses with vaccines: immunological considerations. Bull World Health Organ 1994; 72:973&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486742</ArticleId><ArticleId IdType="pubmed">7867144</ArticleId></ArticleIdList></Reference><Reference><Citation>Caceres VM, Sutter RW. Sabin monovalent oral polio vaccines: review of past experiences and their potential use after polio eradication. Clin Infect Dis 2001; 33:531&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">11462191</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Sayed N, Al-Jorf S, Hennessey KA, et al. Survey of poliovirus antibodies during the final stage of polio eradication in Egypt. Vaccine 2007; 25:5062&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">17543428</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Rapid assessment of serological response to oral polio vaccine. Wkly Epidemiol Rec 1990; 5:34&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">2386716</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantzidou F, Diza E, Halkia D, Antoniadis A. A seroprevalence study of poliovirus antibody in the population of northern Greece. Clin Microbio Infect 2005; 11:68&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15649308</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen RT, Hausinger S, Dajani AS, et al. Seroprevalence of antibody against poliovirus in inner-city preschool children. Implications for vaccination policy in the United States. JAMA 1996; 275:1639&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">8637136</ArticleId></ArticleIdList></Reference><Reference><Citation>Rumke HC, Oostvogel PM, Van Steenis G, Van Loon AM. Poliomyelitis in The Netherlands: a review of population immunity and exposure between the epidemics in 1978 and 1992. Epidemiol Infect 1995; 115:289&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2271413</ArticleId><ArticleId IdType="pubmed">7589268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoub BD, Blackburn NK, McAnerney JM. Seroprevalence to polio in personnel at a virology institute. J Infect 2001; 43:128&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676519</ArticleId></ArticleIdList></Reference><Reference><Citation>Deshpande JM, Kamat JR, Rao VK, et al. Prevalence of antibodies to polioviruses &amp; enteroviruses excreted by healthy children in Bombay. Indian J Med Res 1995; 101:50&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">7729847</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Multicentre Growth Reference Study Group: WHO Child Growth Standards: Length/ height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: Methods and development. Geneva: World Health Organization, 2006. http://www.who.int/childgrowth/standards/technical_report/en/index.html.
Accessed on
17 March 2010.</Citation></Reference><Reference><Citation>Expanded Programme on Immunization. Report of a WHO Informal consultation on polio neutralizing antibody assays, Nashville, 5&#x2013;6 December 1991. Geneva: World Health Organization, 1991. (WHO/EPI/RD/91.3 Rev 1).</Citation></Reference><Reference><Citation>World Health Organization Collaborative Study Group on Oral Poliovirus Vaccine. Factors affecting the immunogenicity of oral poliovirus vaccine: a prospective evaluation in Brazil and the Gambia. J Infect Dis 1995; 171:1097&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">7751683</ArticleId></ArticleIdList></Reference><Reference><Citation>SAS/STAT user&#x2019;s guide, version 6.4 4th ed, vol. 1. Cary, NC: SAS Institute, 1989.</Citation></Reference><Reference><Citation>Census of India. Basic data sheet. District Moradabad (04), Uttar Prades (09). http:censusindia.ogv.in/Dist_File/datasheet-0904.pdf.
Accessed
12 November 2013.</Citation></Reference><Reference><Citation>Government of India Ministry of Health and Family Welfare. District household and facility survey (DLHS-3): 2007&#x2013;08. http://www.rchiips.org.
Accessed
12 November 2013.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication&#x2013;South-East Asia, January 2000&#x2013;June 2001. Morb Mortal Wkly Rep 2001; 50:738&#x2013;42, 751.</Citation><ArticleIdList><ArticleId IdType="pubmed">11787582</ArticleId></ArticleIdList></Reference><Reference><Citation>National Polio Surveillance Project. AFP and polio data. http://www.npspindia.org.
Accessed
12 November 2013.</Citation></Reference><Reference><Citation>el-Sayed N, el-Gamal Y, Abbassy AA, et al. Monovalent type 1 oral poliovirus vaccine in newborns. N Eng J Med 2008; 359:1655&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">18923170</ArticleId></ArticleIdList></Reference><Reference><Citation>John TJ, Jain H, Ravishankar K, et al. Monovalent type 1 oral poliovirus vaccine among infants in India: report of two randomized double-blind controlled clinical trials. Vaccine 2011; 29:5793&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pubmed">21641951</ArticleId></ArticleIdList></Reference><Reference><Citation>Patriarca PA, Wright PF, John TJ. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991; 13:926&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">1660184</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Progress toward poliomyelitis eradication&#x2013;India, January 2007-May 2009. MMWR Morb Mortal Wkly Rep 2009; 58:719&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">19590492</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Update on vaccine-derived polioviruses &#x2014; worldwide, July 2009&#x2013;March 2011. MMWR Morb Mortal Wkly Rep 2011; 60:846&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">21716199</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>